LBA71 Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study).
Saved in:
| Title: | LBA71 Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study). |
|---|---|
| Authors: | Conteduca, V.1 (AUTHOR), Brighi, N.2 (AUTHOR), Gurioli, G.3 (AUTHOR), Wetterskog, D.4 (AUTHOR), Giunta, E.F.2 (AUTHOR), Lolli, C.2 (AUTHOR), Schepisi, G.2 (AUTHOR), Chiuri, V.E.5 (AUTHOR), Gasparro, D.6 (AUTHOR), Zucali, P.A.7 (AUTHOR), Virga, A.3 (AUTHOR), Bondi, I.8 (AUTHOR), Vertogen, B.8 (AUTHOR), Di Iorio, V.9 (AUTHOR), Sansovini, M.10 (AUTHOR), Severi, S.10 (AUTHOR), Scarpi, E.8 (AUTHOR), Urbini, M.3 (AUTHOR), Attard, G.4 (AUTHOR), De Giorgi, U.2 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1259-S1259. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
